Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis.

Abstract

Etravirine is metabolized by three cytochrome P450 enzymes that are in turn induced by rifampin. Consequently, co-administration of etravirine and rifampin is not recommended. To date, however, no clinical studies exploring the drug-drug interaction of this combination have been conducted. Here we report two cases of off-label etravirine use concurrently with antitubercular treatment, dictated by the unavailability of other treatments. Plasma drug concentrations were monitored by regular measurements. Our results appear to confirm the increased metabolism of etravirine through the induction of cytochrome P450 enzymes, but the adequacy of drug levels in all of the measurements and subsequent virological suppression suggest that this drug interaction may not be clinically relevant.

DOI: 10.1007/s15010-014-0599-z
0204060201520162017
Citations per Year

Citation Velocity: 8

Averaging 8 citations per year over the last 3 years.

Learn more about how we calculate this metric in our FAQ.

Cite this paper

@article{Gagliardini2014PharmacokineticsOE, title={Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis.}, author={Roberta Gagliardini and Massimiliano Fabbiani and Stefania Fortuna and Elena Visconti and Pierluigi Navarra and Roberto Cauda and Manuela Colafigli and Andrea De Luca and E M Trecarichi and Simona di Giambenedetto}, journal={Infection}, year={2014}, volume={42 4}, pages={775-8} }